Your browser doesn't support javascript.
loading
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.
Thiery-Vuillemin, Antoine; de Bono, Johann; Hussain, Maha; Roubaud, Guilhem; Procopio, Giuseppe; Shore, Neal; Fizazi, Karim; Dos Anjos, Gabriel; Gravis, Gwenaelle; Joung, Jae Young; Matsubara, Nobuaki; Castellano, Daniel; Degboe, Arnold; Gresty, Chris; Kang, Jinyu; Allen, Allison; Poehlein, Christian; Saad, Fred.
Afiliación
  • Thiery-Vuillemin A; Department of Medical Oncology, Centre Hospitalier Universitaire Besançon, Besançon, France. Electronic address: a.thieryvuillemin@mac.com.
  • de Bono J; The Institute of Cancer Research, Royal Marsden, London, UK.
  • Hussain M; Robert H Lurie Comprehensive Cancer Center, School of Medicine, Northwestern University Feinberg, Chicago, IL, USA.
  • Roubaud G; Department of Medical Oncology, Institut Bergonié, Bordeaux, France.
  • Procopio G; Medical Oncology Dept, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Shore N; Carolina Urologic Research Center, Myrtle Beach, SC, USA.
  • Fizazi K; Institut Gustave Roussy, University of Paris Saclay, Paris, France.
  • Dos Anjos G; Hospital Ernesto Dornelles, Porto Alegre, Brazil.
  • Gravis G; Centre de Recherche en Cancérologie de Marseille, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France.
  • Joung JY; Center for Prostate Cancer, National Cancer Center, Goyang, South Korea.
  • Matsubara N; Department of Breast and Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Castellano D; Hospital Universitario, Madrid, Spain.
  • Degboe A; AstraZeneca, Gaithersburg, MD, USA.
  • Gresty C; AstraZeneca, Cambridge, UK.
  • Kang J; AstraZeneca, Gaithersburg, MD, USA.
  • Allen A; AstraZeneca, Gaithersburg, MD, USA.
  • Poehlein C; Merck, Kenilworth, NJ, USA.
  • Saad F; Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
Lancet Oncol ; 23(3): 393-405, 2022 03.
Article en En | MEDLINE | ID: mdl-35157830
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Médicos / Neoplasias de la Próstata Resistentes a la Castración Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adolescent / Adult / Humans / Male Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Médicos / Neoplasias de la Próstata Resistentes a la Castración Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adolescent / Adult / Humans / Male Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article